Phase 1b LANTERN clinical study is assessing tolododekin alfa, anchored IL-12 immunotherapy, in combination with anti PD-1/PD-L1 immune checkpoint bl...
Thermo Fisher Scientific Inc., the world leader in serving science, announced the enrollment of the first patient in the new PPD™ CorEvitas&t...
Nxera Pharma Co., Ltd. announced a focused restructuring designed to concentrate investment and resources on efficient platforms, programs and products w...
Halda to be acquired by Johnson & Johnson for $3.05 billion in cash Halda recently presented positive Phase 1/2 data for HLD-0915 in metastatic ca...
Third Rock Ventures and Parse Biosciences announced a strategic collaboration to create an unprecedented atlas of 5 million T cell receptors (TCRs)...
Sarepta Therapeutics, Inc. the leader in precision genetic medicine for rare diseases, announced an update to the prescribing information for ELEVI...
Each shareholder is estimated to receive US$1.82 per share plus one CVR per common share - - Transaction expected to close in the first quarter of 20...
Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. Food and Drug Administration (FD...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a U.S.-based global leader in cell therapy, announced the official opening and ribbon c...
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and the Open Applications Group, Inc. (OAGi) are proud to announc...
Streamlined, high-throughput sequencing of Influenza A virus with integrated indexing for Oxford Nanopore Technologies® platforms New England Biolab...
Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare indust...
Launched its first Asia office to support biotech and healthtech innovation and collaboration within the region The Asia office will house the Angelin...
Net sales increase organically by +5.2% to € 5.3 billion; foreign exchange effects of –4.9%, portfolio effects of +0.7% EBI...
© 2026 Biopharma Boardroom. All Rights Reserved.
